...
首页> 外文期刊>Thoracic cancer. >Long‐term survival for 93 months of limited‐stage small cell lung cancer: A case report and literature review
【24h】

Long‐term survival for 93 months of limited‐stage small cell lung cancer: A case report and literature review

机译:有限期小细胞肺癌93个月的长期生存:一例病例报告和文献复习

获取原文
   

获取外文期刊封面封底 >>

       

摘要

AbstractA 49-year-old man was diagnosed with small cell lung cancer in May 2005. Chemotherapy was started with 60 mg/day cisplatin iv drip (from days one to three), 2 mg topotecan (TP) hydrochloride iv drip (from days one to four), and traditional Chinese medicine (TCM) AiDi injection for anti-tumor. After four cycles, he underwent conformal radiotherapy with 56Gy/28 fractions in October 2005. In April 2006, a mass on the right supraclavicular area was found. Therefore, he underwent another course of radiotherapy. The fields included the right supraclavicular area and the radiation dose was 50Gy/25 fractions. After completion of chemoradiotherapy, the patient achieved complete remission. Subsequently, the patient received prophylactic cranial irradiation (PCI). Until April of 2012, he had been followed up regularly. Since the SCLC diagnosis, he had received TCM for seven years. In April 2012, the patient complained of coughing again. Subsequently, the patient was given five cycles of an etoposide carboplatin regimen. A computed tomography (CT) scan was performed for review, which showed no obvious change. The patient underwent a second-line chemotherapy irinotecan cisplatin three times. However, the symptoms and CT of this patient showed no significant improvement. We changed the chemotherapy regimen to TP (topotecan 1.2 mg iv drip, days one to five; carboplatin 100 mg iv drip, days one to five). After two TP regimens, the patient died in his sleep on 3 March 2013. In this case, the standardized sequential chemotherapy and radiotherapy treatment, PCI, TCM, and good compliance may have contributed to the patient's longer survival.
机译:摘要2005年5月,一名49岁的男性被诊断出患有小细胞肺癌。开始化疗时,每天60毫克/天的顺铂静脉滴注(从第1天到第3天),2毫克的托泊替康(TP)盐酸盐静脉滴注(从第1天开始)。至四),以及中药(TCM)艾迪注射液用于抗肿瘤。经过四个周期后,他于2005年10月接受了56Gy / 28分数的适形放疗。2006年4月,在右锁骨上区域发现了肿块。因此,他接受了另一疗程的放射治疗。视野包括右锁骨上区域,辐射剂量为50Gy / 25分数。化学放疗完成后,患者完全缓解。随后,患者接受了预防性颅脑照射(PCI)。直到2012年4月,他都得到了定期跟踪。自从SCLC诊断以来,他已经接受了7年中医治疗。 2012年4月,患者抱怨再次咳嗽。随后,为患者提供了五个周期的依托泊苷卡铂方案。进行了计算机断层扫描(CT)扫描以进行检查,结果无明显变化。该患者接受了三线伊立替康顺铂二线化疗。但是,该患者的症状和CT均未见明显改善。我们将化疗方案改为TP(拓扑替康1.2 mg静脉滴注,第1至5天;卡铂100 mg静脉滴注,第1至5天)。经过两次TP方案后,患者于2013年3月3日在睡眠中死亡。在这种情况下,标准化的序贯化学疗法和放射疗法,PCI,TCM和良好的依从性可能有助于患者更长的生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号